Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity

DSpace/Manakin Repository

Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity

Citable link to this page

. . . . . .

Title: Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity
Author: Kim, Sandra
Citation: Atypical Antipsychotic Drugs for Schizophrenia: Access, Reimbursement and the Struggle for Parity (2002 Third Year Paper)
Full Text & Related Files:
Abstract: This paper discusses the impact of schizophrenia on American society and advocates for health care reform to address the lack of access by the mentally ill to a class of innovative drugs, called “atypical anti-psychotics.†Atypical anti-psychotic drugs, including clozapine, risperidone and olanzapine are crucial for the treatment of both the positive and negative symptoms of schizophrenia and should be made available as first-line treatments for schizophrenics. Current health care policies and reforms provide facially attractive benefits, but lack significant practical benefits, resulting in obstacles to access to these life-changing medications. Health care reforms providing adequate reimbursement for these medications, and thereby opening access to them on a first-line basis, would in fact relieve financial pressures on our health care system instead of creating further strain on scarce resources by reducing funds spent on hospitalization and other medical resources.
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965593

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters